Pharmacokinetics of alendronate

Clinical Pharmacokinetics

Volumn 36, Issue 5, 1999, Pages 315-328

  Porras, Arturo G ^a   Holland, Sherry D ^a   Gertz, Barry J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; CORTICOSTEROID;

BONE; BONE TURNOVER; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG UPTAKE; FOOD DRUG INTERACTION; GLOMERULUS FILTRATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; STOMACH PH; URINARY EXCRETION;

EID: 0033051107     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199936050-00002     Document Type: Review

References (49)

1. 1. Russell RG, Rogers MJ. Introduction to bisphosphonates and the clinical pharmacology of alendronate. Br J Rheumatol 1997; 36: 10-4
2. 2. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19 (1): 80-100
3. 3. Fleisch H, Russell RG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 1966; 212: 901-3
4. 4. Nussbaum S, Warrell R, Rude R, et al. Treatment of cancer-associated hypercalcemia with alendronate (aminohydroxbutylidene bisphosphonate) [abstract]. Proc Am Soc Clin Oncol 1992; 11: 377
5. 5. Warrell R, Mullane M, Bilezikian J, et al. Treatment of cancer-associated hypercalcemia with alendronate sodium: a randomized double-blind comparison with etidronate [abstract]. Proc Am Soc Clin Oncol 1993; 12: A1514
6. 6. Rizzoli R, Buchs B, Bonjour J-P. Effect of a single infusion of alendronate in malignant hypercalcemia; dose dependency and comparison with clodronate. Int J Cancer 1992; 50: 706-12
7. 7. Kanis JA, Gertz BJ, Singer F, et al. Rationale for the use of alendronate in osteoporosis. Osteoporosis Int 1995; 5 (1): 1-13
8. 8. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-43
9. 9. Chestnut CH, McClung MR, Ensrud KE, et al. Alendronate treatment of postmenopausal osteoporotic women: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995; 99: 144-52
10. 10. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-41
11. 11. Devogelaer JP, Broll H, Correa-Rotter R, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996, 18 (2): 141-50
12. 12. Stock JL, Bell NH, Chestnut CH, et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 1997; 103: 291-7
13. 13. Karpf DB, Shapiro DR, Seeman E, et al. Prevention of non-vertebral fractures by alendronate. JAMA 1997; 277 (14): 1159-64
14. 14. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998; 339: 292-9
15. 15. Burssens A, Gertz BJ, Francis RM, et al. A double-blind, placebo controlled, rising multiple dose trial of oral alendronate in Paget's disease. J Bone Miner Res 1990; 5 Suppl. 2: S239
16. 16. Khan SA, Vasikaran S, McCloskey EV, et al. Alendronate in the treatment of Paget's disease of bone. Bone 1997; 20 (3): 263-71
17. 17. Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 1996; 81 (3): 961-7
18. 18. Reid IR, Nicholson GC, Weinstein RS, et al. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med 1996; 171 (4): 341-8
19. 19. Rodan GA. Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol 1998; 38: 375-88
20. 20. Lin JH, Duggan DE, Chen IW, et al. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos 1991; 19 (5): 926-32
21. 21. Sato M, Grasser W, Endo N, et al. Bisphosphonate action, alendronate localization in rat bone and effects on osteoclast. J Clin Invest 1991: 88 (6): 2095-105
22. 3H etidronate in rat and mouse bones. Bone 1996; 19 (3): 281-90
23. 23. Zimolo Z, Wesolowski G, Rodan GA. Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin. J Clin Invest 1995; 96 (5): 2277-83
24. 24. Opas EE, Rutledge SJ, Golub E, et al. Alendronate inhibition of protein-tyrosine-phosphatase-megl. Biochem Pharmacol 1997; 54: 721-7
25. 25. Schmidt A, Rutledge SJ, Endo N, et al. Protein-tyrosine phosphatase activity regulates osteoclast formation and function; inhibition by alendronate. Proc Natl Acad Sci USA 1996; 93: 3068-73
26. 26. Skorey K, Ly HD, Kelly J, et al. How does alendronate inhibit protein-tyrosine phosphatases? J Biol Chem 1997; 272 (36): 22472-80
27. 27. Fisher JE, Rogers MJ, Halasy JM, et al. Alendronate mechanism of action; geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 1999; 96: 133-8
28. 28. Luckman SP, Coxon FP, Ebetino FH, et al. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 1998; 13 (11): 1668-78
29. 29. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10: 1478-87
30. 30. Sahni M, Gucnther HL, Fleisch H, et al. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993; 91 (5): 2004-11
31. 31. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18 (2): 75-85
32. 32. Frith JC, Monkkonen J, Blackburn GM, et al. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(β.γ-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997; 12 (9): 1358-67
33. 33. Lin JH, Chen I-W, deLuna FA. On the absorption of alendronate in rats. J Pharm Sci 1994; 83: 1741-6
34. 34. Lin JH, Chen I-W, deLuna FA. The role of calcium in plasma protein binding and renal handling of alendronate in hyperand hypocalcemic rats. J Pharmacol Exp Ther 1993; 267: 670-5
35. 35. Lin JH, Chen I-W, deLuna FA. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic hisphosphonate, in rats. Drug Metab Dispos 1992; 20: 473-8
36. 36. Lin JH, Chen I-W, deLuna FA. Renal handling of alendronate in rats: an uncharacterized renal transport system. Drug Metab Dispos 1992; 20: 608-13
37. 37. Kline WF, Matuszewski BK. Improved determination of the hisphosphonate alendronate in human plasma and urine by automated precolumn derivalization and high performance liquid chromatography with fluorescence and electrochemi cal detection. J Chromatogr 1992; 583: 183-93
38. 38. Data on file, Merck Research Laboratories
39. 39. Cocquyt V, Kline SF, Gertz BJ, et al. Pharmacokinetics of intravenous alendronate. J Clin Pharmacol 1999 Apr; 39 (4): 385-93
40. 40. Khan SA, Kanis JA, Vasikaran S, et al. Elimination and bio chemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997; 12 (10): 1700-7
41. 41. Gertz BJ, Holland SD, Kline WF, et al. Studies of the oral bioavailability of ulendronate. Clin Pharm Ther 1995; 58 (3): 288-98
42. 42. Physician's desk reference. 52nd ed. Montvale (NJ); Medical Economics Co., Inc. 1998: 1657-61
43. 43. De Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335 (14); 1016-21
44. 44. Dempster DW. Bone remodeling in osteoporosis. In: Riggs BL, Melton LJ, editors. Osteoporosis, etiology, diagnosis and management. 2nd ed. New York; Lippincott-Raven, 1995: 67-92
45. 45. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338 (11): 736-46
46. 46. Harris ET, Gertz BJ, Genant HK, et al. The effect of short-term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 1993; 76 (6): 1399-403
47. 47. Garnero P, Delmas PD. New developments in biochemical markers of osteoporosis. Calcif Tissue Int 1996; 59 Suppl. 1: S2-9
48. 48. Gamero P, Shih WJ, Gineyts E, et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79: 1693-700
49. 49. Siris ES. Clinical review: Paget's disease of bone. J Bone Miner Res 1998; 13 (7): 1061-5